Key result
Valvular heart disease, particularly aortic stenosis, frequently coexists with cardiac amyloidosis, and patients with both conditions experience worse outcomes than those with either condition alone.
Why the study?
Amyloid infiltration of cardiac valves impairs valve structure and function, impacting prognosis, while diagnosis is challenging and data on MR and TR remain limited.
This review highlights the clinical implications and therapeutic options for valvular heart disease in patients with cardiac amyloidosis, noting that TAVR may be a useful strategy for those with concurrent aortic stenosis.
Answers are grounded in this paper and cite their sources.
Valve involvement in CA signals high-risk disease warranting closer monitoring; leaves open prospective trials on targeted valve therapies.
Cardiac amyloidosis (CA) is an underdiagnosed condition caused by the deposition of misfolded proteins, namely immunoglobulin light chains and transthyretin, in the extracellular spaces of the heart. Any cardiovascular structure can be affected by amyloid infiltration, including the valves. Amyloid accumulation within the cardiac valves may lead to their structural and functional impairment, with a profound impact on patients' prognosis and quality of life. The most common forms of valvular disease in CA are aortic stenosis (AS), mitral regurgitation (MR), and tricuspid regurgitation (TR). CA and AS share similar risk factors, disease mechanisms, and remodeling patterns, which make their diagnosis particularly challenging. Patients with both CA and AS experience worse outcomes than CA or AS alone, and transcatheter aortic valve replacement may represent a useful therapeutic strategy in this population. Data on MR and TR are quite limited and mainly coming from case reports or small series. This review paper will summarize our current understanding on the epidemiology, disease mechanisms, echocardiographic features, clinical implications, and therapeutic options of AS, MR, and TR in patients with CA.
No takes yet. Share an insight, caveat, or question.
Aimo et al. (2023) conducted a review in Cardiac amyloidosis and valvular heart disease. Valvular heart disease, particularly aortic stenosis, frequently coexists with cardiac amyloidosis, and patients with both conditions experience worse outcomes than those with either condition alone.
Synapse has enriched 10 related papers. Consider them for comparative context: